- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07928167
Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients
A Randomized Phase 2 Trial of Lenvatinib Plus Pembrolizumab With or Without Stereotactic Radiation Therapy in Patients With Clear-cell Metastatic Renal Cell Carcinoma, Low Tumor Burden, and Stable Disease.
Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Metastatic clear cell renal cell carcinoma (mRCC) is sensitive to combination of lenvatinib and pembrolizumab. The CLEAR study showed positive results in patients with low tumor burden. However, around 20% of patients do not respond and have stable disease. In the VOLGA study, we demonstrated better outcomes in patients with irradiation of even a single lesion during targeted therapy. Thus, investigators hypothesize that stereotactic radiotherapy (SBRT) to multiple lesions in patients undergoing ongoing therapy with pembrolizumab and lenvatinib will increase the objective response rate, which may correlate with improved overall survival.
LASER is a randomized multicenter phase 2 study. Initially, all patients with histologically confirmed mRCC, the median sum of the diameters of target lesions ≥ 7 cm, ECOG 0-2, and the absence of prior systemic therapy for metastatic disease will receive a 12-week induction with lenvatinib and pembrolizumab, followed by radiological assessment according to RECIST 1.1 and allocation by outcome (response, stable disease, or disease progression). Patients with stable disease (SD) will be randomized in a 1:1 ratio into two groups: 1) lenvatinib + pembrolizumab + SBRT (N=27) or 2) lenvatinib + pembrolizumab alone (N=27). In the SBRT group, the choice of target for irradiation - up to 3 (three) lesions - is determined by a multidisciplinary team. The primary endpoint is the objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease (assessed every 12 weeks according to RECIST 1.1). The statistical hypothesis is based on an expected ORR of 15% in the control group versus 50% in the SBRT group. A two-sided α of 0.05 and a power of 80% require 27 patients in each group (54 randomized). The total enrollment will be 150 patients.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Ilya Tsimafeyeu
- Numero di telefono: +74999054690
- Email: sten_to@mail.ru
Luoghi di studio
-
-
-
Kazan', Russia, 420000
- Reclutamento
- Republican Dispensary of Tatarstan
-
Contatto:
- Milyausha Mukhitova
- Numero di telefono: +74999054690
- Email: sten_to@mail.ru
-
Moscow, Russia, 115478
- Reclutamento
- N.N. Blokhin National Medical Research Center of Oncology
-
Contatto:
- Petr Bulychkin
- Numero di telefono: +74999054690
- Email: sten_to@mail.ru
-
Moscow, Russia, 125630
- Reclutamento
- STOONCO clinic
-
Contatto:
- Valentina Leonenko
- Numero di telefono: +7 (915) 809-03-03
- Email: bucare@bucare.org
-
Orenburg, Russia, 460000
- Reclutamento
- Orenburg Regional Cancer Center
-
Contatto:
- Makhabbat Murzalina
- Numero di telefono: +74999054690
- Email: sten_to@mail.ru
-
Saint Petersburg, Russia, 194291
- Reclutamento
- SBHI Leningrad Regional Clinical Hospital
-
Contatto:
- Andrey Lebedinets
- Numero di telefono: +74999054690
- Email: sten_to@mail.ru
-
Tyumen, Russia, 625000
- Reclutamento
- Cancer Center "Medical City"
-
Contatto:
- Vera Peryshkina
- Numero di telefono: +74999054690
- Email: sten_to@mail.ru
-
Ufa, Russia, 450000
- Reclutamento
- Republican Clinical Oncology Dispensary
-
Contatto:
- Alexander Sultanbaev
- Numero di telefono: +7 (347) 216-3671
- Email: ufa.rkod@doctorrb.ru
-
Ulyanovsk, Russia, 432000
- Reclutamento
- "ErSpace" Radiation Therapy Center
-
Contatto:
- Natalia Dengina
- Numero di telefono: +78422737472
- Email: info@rspei.ru
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed clear-cell renal cell carcinoma.
- Presence of measurable lesions per RECIST 1.1.
- Sum of diameters of target lesions ≤ 7 cm.
- ECOG 0-2.
- No prior systemic therapy for metastatic disease.
Exclusion Criteria:
- Uncontrolled comorbidities that preclude the use of TKI/IO or SBRT.
- Prior SBRT to the lesions planned for irradiation, rendering re-irradiation unsafe.
- Active autoimmune diseases requiring systemic immunosuppressants.
- Symptomatic CNS metastases (patients with asymptomatic metastases may be included).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Lenvatinib + Pembrolizumab + SBRT
|
20 mg orally once daily. 200 mg intravenously every 3 weeks The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion. |
|
Comparatore attivo: Lenvatinib + Pembrolizumab
|
20 mg orally once daily. 200 mg intravenously every 3 weeks |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants with Response of unirradiated lesions according to RECIST v1.1
Lasso di tempo: Percentage of patients with response at week 12
|
Objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease |
Percentage of patients with response at week 12
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Median progression-free survival
Lasso di tempo: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
|
Median overall survival
Lasso di tempo: From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
|
Median duration of response
Lasso di tempo: From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
|
Rate of local control of irradiated lesions
Lasso di tempo: Percentage of stable irradiated lesions at week 12
|
Percentage of stable irradiated lesions at week 12
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Lasso di tempo: Rate of treatment-related adverse events at week 24
|
Rate of treatment-related adverse events at week 24
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Ilya Tsimafeyeu et al. A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).. J Clin Oncol 44, TPS583-TPS583(2026). DOI:10.1200/JCO.2026.44.7_suppl.TPS583
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Processi neoplastici
- Neoplasie urologiche
- Carcinoma
- Neoplasie renali
- Condizioni patologiche, segni e sintomi
- Metastasi neoplastica
- Carcinoma, cellule renali
- Tecniche investigative
- Terapie
- Procedure chirurgiche, operative
- Radioterapia
- Tecniche stereotassiche
- Procedure neurochirurgiche
- pembrolizumab
- Radiochirurgia
- Lenvatinib
Altri numeri di identificazione dello studio
- LASER
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
In accordance with local legislation
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .